Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human CD3. Anti-CD3 Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease [1] [2] [3].
In Vivo, Anti-CD3 Antibody (OKT-3) (20 μg/mouse, i.v., a single dose) results in systemic release of several cytokines, such as iL-2, TNF-α in NOG mice injected with human peripheral blood mononuclear cells.[2]. Anti-CD3 Antibody (OKT-3) (10 mg/kg, i.p., a single dose) prevents graft-versus-host disease in human peripheral blood/umbilical cord blood-induced graft-versus-host disease mice models[3].
In Vitro, Anti-CD3 Antibody (OKT-3) (1 μg/mL, 24-36 h) decreases CD4+ and CD8+ T cell numbers in huCD3εHET cells[1]. Anti-CD3 Antibody (OKT-3) (1-1000 ng/mL, 2 h) leads to the marked proliferation in human peripheral blood mononuclear cells[2].
References:
[1]. Crespo J, et al. A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy. PLoS One. 2021 Feb 17;16(2):e0245917.
[2]. Shiheido H, et al. Modulation of the human T cell response by a novel non-mitogenic anti-CD3 antibody. PLoS One. 2014 Apr 7;9(4):e94324.
[3]. Wunderlich M, et al. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 2014 Jun 12;123(24):e134-44.
In Vivo, Anti-CD3 Antibody (OKT-3) (20 μg/mouse, i.v., a single dose) results in systemic release of several cytokines, such as iL-2, TNF-α in NOG mice injected with human peripheral blood mononuclear cells.[2]. Anti-CD3 Antibody (OKT-3) (10 mg/kg, i.p., a single dose) prevents graft-versus-host disease in human peripheral blood/umbilical cord blood-induced graft-versus-host disease mice models[3].
In Vitro, Anti-CD3 Antibody (OKT-3) (1 μg/mL, 24-36 h) decreases CD4+ and CD8+ T cell numbers in huCD3εHET cells[1]. Anti-CD3 Antibody (OKT-3) (1-1000 ng/mL, 2 h) leads to the marked proliferation in human peripheral blood mononuclear cells[2].
References:
[1]. Crespo J, et al. A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy. PLoS One. 2021 Feb 17;16(2):e0245917.
[2]. Shiheido H, et al. Modulation of the human T cell response by a novel non-mitogenic anti-CD3 antibody. PLoS One. 2014 Apr 7;9(4):e94324.
[3]. Wunderlich M, et al. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 2014 Jun 12;123(24):e134-44.